Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial

By J. Cauley, Larry Norton, Marc E. Lippman, S. Eckert, K. Krueger, D. Purdie, J. Farrerons, A. Karasik, D. Mellstrom, Kong Wah Ng and 9 more. Breast Cancer Research and Treatment, 2004

670 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/1abab73baaee40fc623e41ea4400931383ee66a9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Costantino
2. C. Runowicz
3. D. Wickerham
4. W. Cronin
5. R. Cecchini
6. J. Atkins
7. T. Bevers
8. S. Lippman

Citations in the corpus

• Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (2006, result): “Previous studies have shown that raloxifenedoesnot increase the riskofuterinemalignancywhencomparedwithplacebo.(14,17,20) In the STAR trial, only 59 invasive uterine cancers were diagnosed in both study groups during more than 76 000 woman-years of follow-up.”